Type 2 Diabetes mellitus as an independent predictor of significant fibrosis in treatment-na&#xef;ve chronic hepatitis B patients with concurrent hepatic steatosis

Hepatology

Effectiveness of a model of care based on Fibrosis-4 and liver stiffness measurement for the screening of patients with type 2 diabetes mellitus at risk of advanced liver disease: results from an Italian prospective multicentre study

Am J Gastroenterol

Caviglia GP, Ferro A, D'Ambrosio R, Perbellini R, Lampertico P, Periti G, Valenti L, Ciccioli C, Pennisi G, Petta S, Brodosi L, Petroni ML, Marchignoli F, Pironi L, Sagripanti A, Argenziano ME, Svegliati-Baroni G, Rosso C, Barutta F, Armandi A, Gruden G, Bugianesi E

doi: 10.14309/ajg.0000000000003493

HepatologyFurther Publications

All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease

J Hepatol

Huang SC, Su TH, Tseng TC, Hsu SJ, Hong CM, Lan TY, Liu CH, Yang HC, Liu CJ, Kao JH

doi: 10.1016/j.jhep.2024.12.009

Inflammatory Bowel Disease

Metformin Is Associated With Improved Inflammatory Bowel Disease Outcomes in Patients With Type 2 Diabetes Mellitus: A Propensity-Matched Cohort Study

Inflamm Bowel Dis

Petrov JC, Desai AA, Kochhar GS, Crosby SK, Kinnucan JA, Picco MF, Hashash JG, Farraye FA

doi: 10.1093/ibd/izae147

Inflammatory Bowel Disease

Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab

Adv Ther

Zhdanava M, Kachroo S, Boonmak P, Burbage S, Shah A, Korsiak J, Lefebvre P, Kerner C, Pilon D

doi: 10.1007/s12325-024-02942-6

Hepatitis

Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B

J Hepatol

Buti M, Heo J, Tanaka Y, Andreone P, Atsukawa M, Cabezas J, Chak E, Coffin CS, Fujiwara K, Gankina N, Gordon SC, Janczewska E, Komori A, Lampertico P, McPherson S, Morozov V, Plesniak R, Poulin S, Ryan P, Sagalova O, Sheng G, Voloshina N, Xie Q, Yim HJ, Dixon S, Paff M, Felton L, Lee M, Greene T, Lim J, Lakshminarayanan D, McGonagle G, Plein H, Youssef A, Elston R, Kendrick S, Theodore D

doi: 10.1016/j.jhep.2024.08.010

HepatitisHepatology

High diagnostic value of transient elastography for advanced fibrosis and cirrhosis in patients with chronic hepatitis delta

Clin Gastroenterol Hepatol

Roulot D, Brichler S, Layese R, d'ALTEROCHE L, Ganne-Carrie N, Stern C, Saviano A, Leroy V, Roudot-Thoraval F, de Ledinghen V, DELTAVIR study group

doi: 10.1016/j.cgh.2024.08.008

HepatitisInflammatory Bowel Disease

Efficacy of Vaccination and Revaccination Against Hepatitis B Virus Using 2 Different Strategies in Patients With Inflammatory Bowel Disease

Inflamm Bowel Dis

Markopoulos P, Karmiris K, Dimas I, Voudoukis E, Siakavellas S, Axiaris G, Zacharopoulou E, Zampeli E, Tsironi E, Tzouvala M, Papatheodoridis G, Bamias G

doi: 10.1093/ibd/izae173

Further Publications

Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study

Lancet Gastroenterol Hepatol

Lindfors A, Strandberg R, Hagström H

doi: 10.1016/S2468-1253(24)00313-3

Hepatitis

Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B

N Engl J Med

Hou J, Zhang W, Xie Q, Hua R, Tang H, Morano Amado LE, Yang SS, Peng CY, Su WW, Chuang WL, Kim DJ, Avihingsanon A, Kao JH, Leerapun A, Yuen MF, Asselah T, Liang X, Bo Q, Canducci F, Catanese MT, Chen E, Cheng C, Chughlay F, Das S, Glavini K, Guerreiro N, Huang Y, Kakrana P, Kazma R, Patil A, Pavlovic V, Surujbally B, Triyatni M, Upmanyu R, Wat C, Gane E, Piranga Study Group

doi: 10.1056/NEJMoa2405485

Gastroenterology

Type 2 Diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis

Related content